Results 11 to 20 of about 13,707 (310)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan   +8 more
doaj   +2 more sources

Mepolizumab versus placebo for asthma [PDF]

, 2015
Background Mepolizumab is a human monoclonal antibody against interleukin-5 (IL-5), the main cytokine involved in the activation of eosinophils, which in turn causes airway inflammation.
Alvarez-Cuesta, Armentia, Ayars, Ayars, Ayres, Bel, Berger, Blanken, Blanken, Boever, Boulet, Bousquet, Bousquet, Braman, Brown, Bryant, Bryant, Buhl, Buhl, Buhl, Bush, Busse, Busse, Buttner, Caffarelli, Castro, Castro, Chandra, Chervinsky, Clavel, Corren, Corren, Cruz, Cullell-Young, Djukanovic, Ebner, Eckman, El-Nawawy, Fahy, Fahy, Finn, Flood-Page, Flood-Page, Flood-Page, Flood-Page, Frew, Fuhlbrigge, Garcia, Gauvreau, Gauvreau, Gauvreau, Gauvreau, Gevaert, Gibson, Gordon, Greenberg, Gupta, Haldar, Haldar, Haldar, Han, Hanania, Hanania, Hanania, Hill, Hodsman, Holgate, Hoshino, Humbert, Humbert, Humbert, Jacquemin, Jutel, Kandane-Rathnayake, Kang, Kay, Kips, Kon, Kopp, Kopp, Krishnan, Kulus, Lanier, Lanier, Laviolette, Leckie, Leynadier, Lizaso, Masoli, Massanari, Massanari, Mathur, Menzies-Gow, Menzies-Gow, Metzger, Milgrom, Milgrom, Modlin, Moss, Nair, Nair, Nair, Niven, Noga, Noga, Noonan, Oba, Oh, Ohashi, Ohman, Ohta, Ong, Ortega, Ortega, Parker, Patel, Pauli, Pavord, Pavord, Phipps, Piper, Prieto, Pui, Rensen, Rose, Sakamoto, Scheerens, Scheerens, Siergiejko, Silk, Silkoff, Simoes, Singh, Slavin, Soler, Sorkness, Sthoeger, Sugaya, Swanson, Szymaniak, Tanaka, Terr, Vignola, Wark, Wenzel, Wenzel, Wu, Zetterstrom, Zhu, Zielen   +149 more
core   +6 more sources

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Allergy, Asthma & Clinical Immunology
Background Mepolizumab, the first widely available anti-interleukin 5 biologic, targets eosinophilic inflammation and has been shown in clinical trials to reduce exacerbations, oral corticosteroid dependence, and healthcare utilization in patients with ...
Kenneth R. Chapman, Kathryn Cogger, Erin Arthurs, Callahan LaForty, Shane Golden, Bradley Millson, Koyo Usuba, Christopher Licskai   +7 more
doaj   +2 more sources

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Annals of Medicine
Objectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult ...
Ian Pavord, Robert Chan, Nicola Brown, Peter Howarth, Martyn Gilson, Robert G. Price, Jorge Maspero   +6 more
doaj   +2 more sources

The spectrum of therapeutic activity of mepolizumab [PDF]

Expert Review of Clinical Immunology, 2019
Introduction: The basis of the development of the anti-interleukin-5 monoclonal antibody mepolizumab was the acknowledgment of the crucial importance of this cytokine in promoting eosinophils production, activation, and survival, which is associated with
Cavaliere C., Frati F., Ridolo E., Greco A., de Vincentiis M., Masieri S., Makri E., Incorvaia C.   +7 more
core   +6 more sources

Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level

Scientific Reports
To date, most studies to identify biomarkers associated with response to the anti-interleukin 5 agent, mepolizumab, and to the anti-immunoglobulin E agent, omalizumab have focused on clinically available biomarkers, such as the peripheral blood ...
Ayobami Akenroye, Tanawin Nopsopon, Jonathan J. Hacker, Tanya M. Laidlaw   +3 more
doaj   +2 more sources

A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT) [PDF]

Therapeutic Advances in Respiratory Disease
Background: REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan. Objectives: The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined as use of oral ...
Shih-Lung Cheng, Shu-Min Lin, Chung-Kan Peng, Ming-Cheng Chan, Sheng-Yeh Shen, Ping-Hung Kuo, Chien-Hao Lai, Chou-Chin Lan, Chung-Yu Chen, Ching-Hsiung Lin, Kuang-Ming Liao, Po-Hao Feng, Jiin-Torng Wu, Yu-Feng Wei, Xiaomeng Xu, Rafael Alfonso-Cristancho, Tina Lai, Aldo Navarro, Dominique Milea, Diahn-Warng Perng   +19 more
doaj   +2 more sources

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs

Journal of Asthma and Allergy, 2020
Jean-Pierre Llanos,1 Hector Ortega,1 Michael Bogart,2 Elizabeth R Packnett,3 Janna Manjelievskaia,3 Christopher F Bell,2 Beth Hahn2 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2US Value Evidence and Outcomes, US Medical ...
Llanos JP, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B   +6 more
doaj   +2 more sources

Reappraising the clinical impact of mepolizumab [PDF]

The Lancet Respiratory Medicine, 2017
Chupp, Jones, Jones, Juniper, Santanello, Wenzel   +5 more
core   +7 more sources

Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry [PDF]

The Journal of Allergy and Clinical Immunology: In Practice, 2021
Oral corticosteroids (OCS) carry serious health risks. Innovative treatment options are required to reduce excessive exposure and promote OCS stewardship.This study evaluated the trajectories of OCS exposure (prednisolone-equivalent) in patients with severe eosinophilic asthma before and after starting mepolizumab and the predictors of becoming OCS ...
John W. Upham, John W. Upham, Jimmy Chien, Jimmy Chien, Vanessa M. McDonald, Vanessa M. McDonald, Andrew Gillman, Simon D. Bowler, Vicky Kritikos, Peter G. Gibson, Peter G. Gibson, Naghmeh Radhakrishna, Claude S. Farah, Claude S. Farah, Pathmanathan Sivakumaran, Erin S. Harvey, Erin S. Harvey, Melissa Baraket, Joy Lee, Christopher Grainge, Constance H. Katelaris, Constance H. Katelaris, Jeffrey Bowden, Sean Stevens, Peter A. B. Wark, Peter A. B. Wark, Mark Hew, Helen K. Reddel, Helen K. Reddel, Matthew J. Peters, John Harrington, Paul N. Reynolds, Gregory Katsoulotos, Gregory Katsoulotos, Christine Jenkins, Christine Jenkins, David Langton, David Langton, Dennis Thomas, Janet Rimmer, Philip G. Bardin, Li Ping Chung   +41 more
openaire   +4 more sources